Deerfield Management Company L.P. Series C Sells 471,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Deerfield Management Company L.P. Series C cut its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 55.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 373,407 shares of the company's stock after selling 471,000 shares during the period. Deerfield Management Company L.P. Series C owned 0.65% of Structure Therapeutics worth $10,127,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in GPCR. Spire Wealth Management bought a new stake in Structure Therapeutics during the fourth quarter worth $243,000. JPMorgan Chase & Co. increased its stake in shares of Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after purchasing an additional 25,500 shares during the last quarter. Mariner LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $665,000. Barclays PLC lifted its stake in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after purchasing an additional 31,815 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Structure Therapeutics by 9.4% during the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company's stock worth $30,991,000 after purchasing an additional 60,397 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Trading Down 4.7 %

GPCR traded down $1.26 during trading on Friday, reaching $25.56. 599,275 shares of the company's stock were exchanged, compared to its average volume of 928,882. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The firm has a fifty day moving average price of $20.94 and a two-hundred day moving average price of $26.94. The stock has a market capitalization of $1.47 billion, a PE ratio of -34.54 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GPCR. Citigroup assumed coverage on Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and an average price target of $78.63.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.